On the other hand, a meta-analysis published in 2023, encompassing fifteen studies and involving a total of 2,910,405 diabetic patients, found that antidiabetic medications including metformin, sulfonylureas, glucagon-like peptide-1 agonists, and glitazones did not display any significant association with alterations in the risk of PD [265]. The gene discussed is GCG; the disease is Parkinson disease.